^
    Back
    Association details:
    Biomarker:CTAG1B expression + CTAG2 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:letetresgene autoleucel (GSK3377794) (TCR modulator, NY ESO 1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2020
    Title:

    96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

    Published date:
    11/09/2020
    Excerpt:
    Consistent with our previous in vitro studies, DAC treatment in vivo resulted in induction of NY-ESO-1 and LAGE-1a in NSCLC tumors. Lete-cel in combination with DAC significantly enhanced antitumor efficacy in vivo compared with lete-cel alone.
    Secondary therapy:
    decitabine
    DOI:
    http://dx.doi.org/10.1136/jitc-2020-SITC2020.0096